This study is a multicenter, prospective, observational cohort study designed to enroll a total of 340 patients undergoing allogeneic hematopoietic stem cell transplantation. Through comprehensive evaluations by hematology departments, ophthalmology departments, and patient-reported outcomes, the study aims to assess patient-reported outcomes, overall incidence, risk factors, and other clinical outcomes in patients with chronic ocular graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Study Type
OBSERVATIONAL
Enrollment
340
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
RECRUITINGNEI-VFQ-25 scale
The NEI-VFQ-25 (National Eye Institute Visual Function Questionnaire-25) is a 25-item, vision-specific patient-reported outcome measure. It assesses the impact of visual impairment on health-related quality of life
Time frame: Two years after HSCT
EQ-5D-5L
The EQ-5D-5L is a standardized, generic health status measure developed by the EuroQol Group. It is designed for self-completion and is widely used in clinical and economic evaluations.
Time frame: Two years after HSCT
Lee GVHD scale
The Lee Chronic GVHD Symptom Scale is a patient-reported outcome (PRO) measure developed to assess the symptom burden of chronic graft-versus-host disease (cGVHD)
Time frame: Two years after HSCT
FACT-BMT
The FACT-BMT (Functional Assessment of Cancer Therapy - Bone Marrow Transplantation) is a patient-reported outcome (PRO) measure designed to assess health-related quality of life (HRQoL) in patients undergoing bone marrow or hematopoietic stem cell transplantation
Time frame: Two years after HSCT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.